# Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000

Source: https://onco.cc/ideas/idea-reg-lmic-public-cart-manufacturing/  
OnCo record `idea-reg-lmic-public-cart-manufacturing` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

India has shown CAR-T can be made for a tenth of the US price. Public production in large middle-income countries could make it available to millions who are currently excluded.

## Summary

NexCAR19 (ImmunoACT, Tata Memorial and IIT Bombay) was approved in India in 2023 at around $40,000; Brazil's Fiocruz and Butantan and China's academic centres are building comparable capacity. The proposal is a coordinated public-sector programme in three to five large middle-income countries with shared vector supply, shared training, a common product dossier adapted for national regulators, and outcome registries, aimed at treating relapsed B-cell malignancies at under $50,000 per dose within public health systems.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Public manufacturing programmes treat at least 5,000 patients a year across participating countries within five years at under $50,000 per dose, with complete response rates in relapsed B-ALL and lymphoma comparable to published academic series.
- Rationale: Labour, facility and vector costs are far lower in these settings and the demand is enormous; the Indian precedent shows regulatory approval and manufacturing are achievable, and cross-country sharing of vector and know-how spreads fixed costs.
- Proposed test: Fund two additional national programmes to reach approval using shared vector and process, and report cost, throughput and outcomes at three years against the Indian precedent.
- Maturity: early-clinical
- Actor: policy

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- institutions: [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)
- drugs: [Talicabtagene autoleucel](https://onco.cc/drugs/talicabtagene-autoleucel/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-lmic-public-cart-manufacturing.json